Skip to content

Evaluation of Group Lifestyle Balance DVD in Primary Care Practice

Screening, Training, Education and Prevention Service of the University of Pittsburgh, Phase 2

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00480779
Acronym
STEPUP
Enrollment
48
Registered
2007-05-31
Start date
2007-06-30
Completion date
2009-05-31
Last updated
2016-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Prediabetes

Keywords

Prediabetes, Metabolic syndrome, Prevention, Lifestyle intervention

Brief summary

The purpose of this study is to examine different methods of delivering the Group Lifestyle Balance (GLB) intervention (1). The GLB is a 12-week lifestyle change program based on the highly successful lifestyle program that was used in the Diabetes Prevention Program (DPP)(2). A DVD of the Group Lifestyle Program has been developed. Conditions called metabolic syndrome and pre-diabetes increase the risk of diabetes and heart disease. Recent research has shown that type 2 diabetes and metabolic syndrome may be prevented or delayed by making lifestyle changes. A primary care practice will enroll participants who will choose either the GLB-DVD intervention or face-to-face group delivery. Approximately 25 patients will be recruited in each group. It is not known if the GLB intervention delivered via DVD is similarly effective to face-to-face group delivery for people with metabolic syndrome or pre-diabetes. It is hoped that this research study will provide information to help answer that question.

Detailed description

The Group Lifestyle Balance program is a 12-session lifestyle intervention with the same goals for weight loss and physical activity as the successful Diabetes Prevention Program (DPP) lifestyle intervention and has been evaluated in several settings. The DPSC collaborated with the US Air Force Center of Excellence for Medical Multimedia to create a DVD of the GLB. The GLB-DVD is a series of taped sessions of a staged group following a script that was developed to closely follow the program. Effectiveness was assessed for the intervention delivered via DVD (GLB-DVD) as well as traditionally in a group setting (GLB-GROUP). For each delivery mode, pre- and 3 month post-intervention measures of weight and the achievement of the program goals were assessed. Secondary outcomes measured included assessment of components of the metabolic syndrome (NCEP ATP III) and HbA1c. The prevention professionals in the practice and the Diabetes Prevention Support Center (DPSC) who provided support for the GLB-DVD and GLB-GROUP participants were health care professionals trained in delivery of the GLB by the DPSC faculty. Group delivery of the GLB was conducted via weekly in person, meetings delivered over 12-15 weeks. For GLB-DVD delivery, an overview of the GLB-DVD and materials was provided at commencement of the intervention. Participants were instructed to view one session/week. At the end of each month the participant was asked to return their DVD via postage-paid mail to the DPSC and the next sequential DVD was mailed to the participant. During GLB-DVD delivery, the DPSC prevention professional contacted the participant weekly via telephone to review weight, physical activity minutes, and questions/concerns regarding the program. Thus, participants in both GLB-GROUP and GLB-DVD were offered a total of 12 health care professional contacts. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.

Interventions

BEHAVIORALGLB Group

The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.

BEHAVIORALGLB DVD

The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.

Sponsors

United States Department of Defense
CollaboratorFED
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All non-diabetic patients age 18 years and older at the time of enrollment considered to be patients of the practices that are taking part in this project will be eligible for the study upon referral from their physician. * Non-diabetic patients with metabolic syndrome AND/OR pre-diabetes are eligible for the study with referral from their physician based on the following criteria: * Metabolic Syndrome: Patients with BMI greater than or equal to 25 kg/m2, with at least 3 of the following risk factors for metabolic syndrome: * Waist circumference (\>40 inches men, \>35 inches women) * Blood pressure greater than or equal to 130 mmHg (systolic) and/or 85 mmHg (diastolic) OR history of diagnosed hypertension * Low HDL level (\<40mg/dL men, \<50 mg/dL women) * Elevated triglyceride level greater than or equal to 150 mg/dL * Fasting glucose greater than or equal to 100mg/dL and \<126mg/dL * Pre-diabetes: Patients with a BMI greater than or equal to 25 kg/m2 and pre-diabetes (fasting glucose greater than or equal to 100 mg/dL and \<126mg/dL) * All measures should have been taken within six months of enrollment into the study. The physician in each center will be asked to refer eligible patients to the study. It will be the responsibility of the referring physician to determine eligibility and appropriateness of the patient's participation.

Exclusion criteria

* Those patients age less than 18 years old will not be invited to be part of the study. In addition, patients with any of the following conditions are not eligible to take part in the study: * Those with previous diabetes diagnosis * Women who are currently (or within past 6-weeks) pregnant or lactating * Any patient deemed by their physician not to be a candidate * Any patient planning to leave the area before the end of the program * Individuals that are not patients of the participating primary care practices

Design outcomes

Primary

MeasureTime frameDescription
Change in WeightBaseline and 3 monthsThe primary outcome for this study will be change in weight measured pre and post intervention.

Secondary

MeasureTime frameDescription
Change in Total CholesterolBaseline and 3 monthsA secondary outcome for this study will be change in total cholesterol, measured pre and post intervention.
Change in HDL CholesterolBaseline and 3 monthsA secondary outcome for this study will be change in HDL cholesterol, measured pre and post intervention.
Change in LDL CholesterolBaseline and 3 monthsA secondary outcome for this study will be change in LDL cholesterol, measured pre and post intervention.
Change in Fasting GlucoseBaseline and 3 monthsA secondary outcome for this study will be change in fasting glucose, measured pre and post intervention.
Change in Waist CircumferenceBaseline and 3 monthsA secondary outcome for this study will be change in waist circumference, measured pre and post intervention.
Change in Systolic Blood PressureBaseline and 3 monthsA secondary outcome for this study will be change in systolic blood pressure, measured pre and post intervention.
Change in Diastolic Blood PressureBaseline and 3 monthsA secondary outcome for this study will be change in diastolic blood pressure, measured pre and post intervention.
Change in TriglyceridesBaseline and 3 monthsA secondary outcome for this study will be change in Triglyceride level, measured pre and post intervention.
Change in Hemoglobin A1CBaseline and 3 monthsA secondary outcome for this study will be change in HbA1c, measured pre and post intervention. The hemoglobin HbA1c test provides information regarding how well blood glucose (sugar) has been controlled for the previous 8-12 weeks..

Countries

United States

Participant flow

Recruitment details

Patients meeting the criteria for participation were referred by their health care provider, who also provided approval for moderate intensity physical activity. After completing informed consent, participants chose which mode of delivery they preferred, GLB-DVD or GLB-GROUP.

Participants by arm

ArmCount
GLB Group
The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study chose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
26
GLB DVD
The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study chose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
22
Total48

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyJob and Health-related03
Overall StudyOther20

Baseline characteristics

CharacteristicGLB GroupGLB DVDTotal
Age, Continuous61.0 years
STANDARD_DEVIATION 11.9
57.3 years
STANDARD_DEVIATION 13.6
59.1 years
STANDARD_DEVIATION 12.8
Region of Enrollment
United States
26 participants22 participants48 participants
Sex: Female, Male
Female
21 Participants13 Participants34 Participants
Sex: Female, Male
Male
5 Participants9 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 260 / 22
serious
Total, serious adverse events
0 / 260 / 22

Outcome results

Primary

Change in Weight

The primary outcome for this study will be change in weight measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat using Last Observation Carried Forward (LOCF)

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Weight-13.9 poundsStandard Deviation 14.3
GLB DVDChange in Weight-11.8 poundsStandard Deviation 11.4
Secondary

Change in Diastolic Blood Pressure

A secondary outcome for this study will be change in diastolic blood pressure, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Diastolic Blood Pressure-3.6 mmHgStandard Deviation 7.68
GLB DVDChange in Diastolic Blood Pressure-1.43 mmHgStandard Deviation 6.88
Secondary

Change in Fasting Glucose

A secondary outcome for this study will be change in fasting glucose, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Fasting Glucose1.15 mg/dlStandard Deviation 10.52
GLB DVDChange in Fasting Glucose-4.71 mg/dlStandard Deviation 6.66
Secondary

Change in HDL Cholesterol

A secondary outcome for this study will be change in HDL cholesterol, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in HDL Cholesterol-2.08 mg/dlStandard Deviation 5.9
GLB DVDChange in HDL Cholesterol-0.72 mg/dlStandard Deviation 3.71
Secondary

Change in Hemoglobin A1C

A secondary outcome for this study will be change in HbA1c, measured pre and post intervention. The hemoglobin HbA1c test provides information regarding how well blood glucose (sugar) has been controlled for the previous 8-12 weeks..

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Hemoglobin A1C-0.31 percentage of glycosylated hemoglobinStandard Deviation 0.25
GLB DVDChange in Hemoglobin A1C-0.16 percentage of glycosylated hemoglobinStandard Deviation 0.23
Secondary

Change in LDL Cholesterol

A secondary outcome for this study will be change in LDL cholesterol, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in LDL Cholesterol0.33 mg/dlStandard Deviation 20.87
GLB DVDChange in LDL Cholesterol-2.67 mg/dlStandard Deviation 14.69
Secondary

Change in Systolic Blood Pressure

A secondary outcome for this study will be change in systolic blood pressure, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Systolic Blood Pressure-6.55 mmHgStandard Deviation 11.29
GLB DVDChange in Systolic Blood Pressure-4.95 mmHgStandard Deviation 6.68
Secondary

Change in Total Cholesterol

A secondary outcome for this study will be change in total cholesterol, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Total Cholesterol-8.29 mg/dlStandard Deviation 27.09
GLB DVDChange in Total Cholesterol-9.94 mg/dlStandard Deviation 19.08
Secondary

Change in Triglycerides

A secondary outcome for this study will be change in Triglyceride level, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.

ArmMeasureValue (MEDIAN)
GLB GroupChange in Triglycerides-2.0 mg/dl
GLB DVDChange in Triglycerides0 mg/dl
Secondary

Change in Waist Circumference

A secondary outcome for this study will be change in waist circumference, measured pre and post intervention.

Time frame: Baseline and 3 months

Population: Intent to treat

ArmMeasureValue (MEAN)Dispersion
GLB GroupChange in Waist Circumference-2.49 inchesStandard Deviation 2.08
GLB DVDChange in Waist Circumference-1.87 inchesStandard Deviation 1.98

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026